Oncolytics Biotech (ONCY) Non Operating Investment Income (2019 - 2025)

Oncolytics Biotech (ONCY) has 7 years of Non Operating Investment Income data on file, last reported at -$764420.0 in Q3 2025.

• On a quarterly basis, Non Operating Investment Income fell 555.37% year-over-year to -$764420.0 in Q3 2025; TTM through Sep 2025 was -$803758.0, a 117.69% decrease from a year earlier, with the FY2024 full-year figure at $907156.1, down 76.84% from the prior year.
• Non Operating Investment Income for Q3 2025 stood at -$764420.0, down from -$141455.6 in the prior quarter.
• Over the last five years, Non Operating Investment Income for ONCY reached as high as $3.6 million in Q4 2023 and fell as low as -$764420.0 in Q3 2025.
• Historically, Non Operating Investment Income has averaged $214180.8 across 5 years, with a median of $30589.3 in 2022.
• Across the five-year window, Non Operating Investment Income surged 16761.18% in 2023 and plunged 555.37% in 2025, its largest moves.
• Year by year, Non Operating Investment Income stood at $39194.8 in 2021, then sank by 154.51% to -$21364.4 in 2022, then jumped by 16761.18% to $3.6 million in 2023, then sank by 101.83% to -$65142.3 in 2024, then slumped by 1073.46% to -$764420.0 in 2025.
• Per Business Quant data, the three most recent Non Operating Investment Income figures were -$764420.0 in Q3 2025, -$141455.6 in Q2 2025, and $167260.0 in Q1 2025.